Hyderabad-based biotech begins Phase I study of PVX-001, an mRNA vaccine designed to provide broader protection against emerging SARS-CoV-2 variants
Hyderabad-based biotech company PopVax has taken its experimental COVID-19 vaccine, PVX-001, into human clinical trials, marking a major milestone for India’s emerging AI-driven biotechnology ecosystem.
The first two participants received doses of PVX-001 on August 31, 2026, in Melbourne, Australia, in the company’s first-in-human Phase I study. According to PopVax, 14 participants had been enrolled and dosed by October 6, with no serious adverse events reported to date. The trial is planned to include 36 healthy adults and will evaluate the vaccine’s safety, tolerability and immune response.
Designing for the next generation of variants
PVX-001 is being developed as a broadly protective COVID-19 vaccine, with the goal of generating immune responses that can recognise multiple SARS-CoV-2 variants.
The vaccine combines mRNA technology with a virus-like particle (VLP) approach. Rather than simply instructing cells to produce the viral antigen, PVX-001’s mRNA is designed to produce a protein that self-assembles into VLPs displaying multiple copies of an engineered SARS-CoV-2 receptor-binding domain.
This repeated antigen display is designed to stimulate a stronger and broader antibody response.
In preclinical studies, PopVax reports that its RNA-encoded VLP approach generated substantially higher neutralising antibody responses in mice compared with mRNA encoding the same antigen without VLP display. The company also reported neutralisation against multiple SARS-CoV-2 variants.
Built in India, tested globally
A notable feature of the programme is its full-stack development approach.
PopVax has developed its computational protein-design platform, mRNA technology, lipid nanoparticle delivery system and clinical-dose manufacturing capabilities in India. The company’s RNA Foundry in Hyderabad produces the mRNA-LNP vaccine and has been built to support rapid development of new RNA medicines.
The company’s proprietary ionisable lipid, PVXL-150, is designed to enable refrigerator-temperature storage. PopVax reports that its formulation can remain stable at 2–8°C for at least nine months, potentially simplifying distribution compared with the ultracold storage requirements of some early mRNA COVID-19 vaccines.
The clinical programme also reflects international collaboration. The project has received support from the Gates Foundation, Balvi and Good Ventures and was part of the US Project NextGen initiative. Clinical testing is being conducted by Nucleus Network in Melbourne.
From computational design to the clinic
For PopVax, PVX-001 represents the first major clinical milestone for a broader technology platform aimed at rapidly developing vaccines and therapeutics.
The company is already working on additional vaccine programmes targeting rabies, hepatitis C, tuberculosis and Group A Streptococcus, alongside programmes in cancer and autoimmune disease.
PopVax has also announced plans to open-source PVX-001’s design and manufacturing information after completion of the Phase I trial, with the stated goal of enabling researchers and manufacturers worldwide to build on the technology for betacoronavirus vaccines.
The move from computational protein design to a vaccine being administered to humans represents a significant step for PopVax—and a notable moment for India’s ambitions in next-generation biotechnology.
The PVX-001 trial now brings that vision into the clinic.
Original Source: PopVax Goes Clinical — The PopVax Chronicles
